| Budget Amount *help |
¥86,060,000 (Direct Cost: ¥66,200,000、Indirect Cost: ¥19,860,000)
Fiscal Year 2014: ¥15,470,000 (Direct Cost: ¥11,900,000、Indirect Cost: ¥3,570,000)
Fiscal Year 2013: ¥16,250,000 (Direct Cost: ¥12,500,000、Indirect Cost: ¥3,750,000)
Fiscal Year 2012: ¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2011: ¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2010: ¥20,670,000 (Direct Cost: ¥15,900,000、Indirect Cost: ¥4,770,000)
|
|---|
| Outline of Final Research Achievements |
In this project, we tried to analyze the regulation of metastasis-promoting activities of Merm1 and Aggrus by tumor microenvironment and to develop anti-metastatic drugs. We performed the following experiments and obtained several new findings.
(1) We found that Merm1 enhanced tumor cell survival in the vasculature by suppressing p53-mediated apoptosis. We established the in vivo screening system to select high metastatic tumors and obtained several candidate metastasis-related genes.
(2) We analyzed the role of platelets in tumor growth and metastasis. We found that platelets were one of the components of tumor microenvironment, that growth factors secreted from platelets were associated with tumor growth in vivo, and that anti-Aggrus drugs would suppress tumor growth as well as tumor metastasis.
|
